Abstract:Ubiquitination, an important type of protein posttranslational modification (PTM), plays a crucial role in controlling substrate degradation and subsequently mediates the "quantity" and "quality" of various proteins, serving to ensure cell homeostasis and guarantee life activities. The regulation of ubiquitination is multifaceted and works not only at the transcriptional and posttranslational levels (phosphorylation, acetylation, methylation, etc.) but also at the protein level (activators or repressors). When regulatory mechanisms are aberrant, the altered biological processes may subsequently induce serious human diseases, especially various types of cancer. In tumorigenesis, the altered biological processes involve tumor metabolism, the immunological tumor microenvironment (TME), cancer stem cell (CSC) stemness and so on. With regard to tumor metabolism, the ubiquitination of some key proteins such as RagA, mTOR, PTEN, AKT, c-Myc and P53 significantly regulates the activity of the mTORC1, AMPK and PTEN-AKT signaling pathways. In addition, ubiquitination in the TLR, RLR and STING-dependent signaling pathways also modulates the TME. Moreover, the ubiquitination of core stem cell regulator triplets (Nanog, Oct4 and Sox2) and members of the Wnt and Hippo-YAP signaling pathways participates in the maintenance of CSC stemness. Based on the altered components, including the proteasome, E3 ligases, E1, E2 and deubiquitinases (DUBs), many molecular targeted drugs have been developed to combat cancer. Among them, small molecule inhibitors targeting the proteasome, such as bortezomib, carfilzomib, oprozomib and ixazomib, have achieved tangible success. In addition, MLN7243 and MLN4924 (targeting the E1 enzyme), Leucettamol A and CC0651 (targeting the E2 enzyme), nutlin and MI-219 (targeting the E3 enzyme), and compounds G5 and F6 (targeting DUB activity) have also shown potential in preclinical cancer treatment. In this review, we summarize the latest progress in understanding the substrates for ubiquitination and their special functions in tumor metabolism regulation, TME modulation and CSC stemness maintenance. Moreover, potential therapeutic targets for cancer are reviewed, as are the therapeutic effects of targeted drugs.

The role of ubiquitination in tumorigenesis and targeted drug discovery

Roles of Ubiquitination in the Crosstalk Between Tumors and the Tumor Microenvironment (Review)

Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches

Function, mechanism and drug discovery of ubiquitin and ubiquitin-like modification with multiomics profiling for cancer therapy

Targeting the Ubiquitin Pathway for Cancer Treatment

Targeting the Ubiquitin-Proteasome System and Recent Advances in Cancer Therapy

Ubiquitination of Nonhistone Proteins in Cancer Development and Treatment

Targeting the Ubiquitin Signaling Cascade in Tumor Microenvironment for Cancer Therapy

The roles of E3 ubiquitin ligases in cancer progression and targeted therapy

Progress in Anticancer Drug Development Targeting Ubiquitination-Related Factors

Key roles of ubiquitination in regulating critical regulators of cancer stem cell functionality

Emerging Role of DUBs in Tumor Metastasis and Apoptosis: Therapeutic Implication

Clinical and Marketed Proteasome Inhibitors for Cancer Treatment

Involvement of the ubiquitin-proteasome system in the regulation of the tumor microenvironment and progression

The Small Molecules Targeting Ubiquitin-Proteasome System for Cancer Therapy

The Role Of The Ubiquitin-Proteasome Pathway In Cancer Development And Treatment

Emerging Roles of Non-proteolytic Ubiquitination in Tumorigenesis

Control of mTOR signaling by ubiquitin

Ubiquitination of Immune System and Cancer Therapy

Emerging drug development technologies targeting ubiquitination for cancer therapeutics

Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy